A boost for the precision of genome editing
August 20, 2025
August 20, 2025
CAMBRIDGE, Massachusetts, Aug. 20 -- The Massachusetts Institute of Technology issued the following news:
* * *
A boost for the precision of genome editing
*
The U.S. Food and Drug Administration's recent approval of the first CRISPR-Cas9-based gene therapy has marked a major milestone in biomedicine, validating genome editing as a promising treatment strategy for disorders like sickle cell disease, muscular dystrophy, and certain cancers. . . .
* * *
A boost for the precision of genome editing
*
The U.S. Food and Drug Administration's recent approval of the first CRISPR-Cas9-based gene therapy has marked a major milestone in biomedicine, validating genome editing as a promising treatment strategy for disorders like sickle cell disease, muscular dystrophy, and certain cancers. . . .